BRCA1

Breast cancer type 1 susceptibility protein · P38398 · BRCA1 on Sugi Atlas →

55,232 patent compounds predicted against BRCA1, 41,415 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Daunorubicin (SCHEMBL3041)	1.00	7/20
Idarubicin (SCHEMBL4838)	0.98	7/20
Epirubicin (SCHEMBL94408)	0.92	7/20
Carubicin (SCHEMBL4201)	0.85	7/20
Daunorubicin (SCHEMBL42311)	0.85	7/20
SCHEMBL94868	0.84	7/20
Zorubicin (SCHEMBL8231)	0.81	7/20
Zorubicin (SCHEMBL8232)	0.81	7/20
Epirubicin (SCHEMBL3165)	1.00	6/20
Doxorubicin (SCHEMBL3242)	1.00	6/20
Doxorubicin (SCHEMBL3243)	1.00	6/20
Idarubicin (SCHEMBL3750)	1.00	6/20
Daunorubicin (SCHEMBL4444)	1.00	6/20
Daunorubicin (SCHEMBL4445)	1.00	6/20
Epirubicin (SCHEMBL8582)	1.00	6/20
Doxorubicin (SCHEMBL57097)	1.00	6/20
Epirubicin (SCHEMBL95415)	1.00	6/20
Daunorubicin (SCHEMBL122984)	1.00	6/20
Daunorubicin (SCHEMBL142541)	1.00	6/20
Doxorubicin (SCHEMBL177976)	1.00	6/20

Clinical trials — most relevant to BRCA1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer.	PHASE3	COMPLETED
Phase II ABT-888 With Cyclophosphamide	PHASE2	COMPLETED
BRCA1-associated DNA Repair Dysfunction in Patients With Early Triple Negative Breast Cancer Treated With Neoadjuvant Platinum-based Chemotherapy	PHASE2	COMPLETED
AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer	PHASE1	COMPLETED
Adherence to Intensive Surveillance for Hereditary Breast Cancer	nan	COMPLETED
Testing an Intelligent Tutoring System to Enhance Genetic Risk Assessment	nan	COMPLETED
Testing a Culturally Adapted Telephone Genetic Counseling Intervention	nan	COMPLETED
InheriteD brEast caNcer iTalian regIsTrY A Retrospective-prospective Observational Cohort Study to Evaluate Cancer Prevention Strategies in Women With a Deleterious Mutation in BRCA1-2	nan	RECRUITING
Susceptibility to Breast Cancer	nan	COMPLETED
Pregnancy Outcomes After Breast Cancer in Young Women With Germline Pathogenic Variants in Genes Other Than BRCA	nan	NOT_YET_RECRUITING
LobularCard Trial: Searching for Novel Germline Mutations in Lobular Breast Cancer Patients	nan	ACTIVE_NOT_RECRUITING
Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood Samples	nan	RECRUITING
Cluster Randomized Trial Comparing Interventions to Enhance Genetic Counseling Among Breast Cancer Patients	nan	COMPLETED
X-Ray Mammography Standard of Care Protocol	nan	COMPLETED
Prophylactic Irradiation to the Contralateral Breast for BCAs Patients	nan	RECRUITING
Aberrant Expression of Micro RNA for Diagnosis of Breast Cancer	nan	UNKNOWN
Insulin Resistance and Breast Cancer	nan	COMPLETED
A Qualitative Exploration of the Impact of Positive BRCA1/2 Mutation Status on the Lives of Young Women	nan	COMPLETED
Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Annual Follow-Up Study	nan	COMPLETED
Decision Support for BRCA Testing in Ethnically Diverse Women	nan	COMPLETED
Psyco Quality of Life and Procreation BRCA1/2	nan	UNKNOWN
Germline BRCA1 and BRCA2 Mutations in Jewish Women Affected by Breast Cancer	nan	COMPLETED
A Multi Modality Surveillance Program for Women At High Risk for Breast Cancer	nan	ACTIVE_NOT_RECRUITING
Oncotype DX in BRCA-mutated Breast Cancer Patients: Our Experience. A Retrospective Observational Monocentric Study	nan	COMPLETED
CBPR - BRCA Genetic Testing Among Orthodox Jews	nan	COMPLETED
Genetic Predisposition to Breast and Ovarian Cancer: Prospective Study of BRCAx Gene Mutation	nan	RECRUITING
Study on Fertility Parameters in Women With Germline Variants in BRCA1 and BRCA2	nan	NOT_YET_RECRUITING
Characterization of Epithelial Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype	nan	RECRUITING
A 3D Bioprinted Hormone-producing Model for BRCA Mutated Patients After Risk Reducing Surgery: the DISC-OVARY Trial	nan	ACTIVE_NOT_RECRUITING
Women at Risk of Breast Cancer and OLFM4	nan	ACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a BRCA1 binder may also engage these)

Protein	Name	Similarity
Q6J6I9	—	1.000	Q6J6I9 →
Q6J6J0	—	1.000	Q6J6J0 →
Q9GKK8	—	1.000	Q9GKK8 →
Q6J6I8	—	0.999	Q6J6I8 →
Q864U1	—	0.998	Q864U1 →
F6ULY3	—	0.998	F6ULY3 →
E5FYH1	—	0.997	E5FYH1 →
E5FYH0	—	0.996	E5FYH0 →
Q8N9V7	—	0.994	Q8N9V7 →
MAP3K19	Mitogen-activated protein kinase kinase kinase 19	0.994	landscape →
Q864S8	—	0.994	Q864S8 →
Q95153	—	0.994	Q95153 →
O54952	—	0.993	O54952 →
G7H7V7	—	0.992	G7H7V7 →
Q7Z570	—	0.992	Q7Z570 →
P51587	—	0.992	P51587 →
G7NY55	—	0.991	G7NY55 →
P48754	—	0.991	P48754 →
Q8N7Z5	—	0.991	Q8N7Z5 →
F7DF15	—	0.991	F7DF15 →
A0A140LI88	—	0.990	A0A140LI88 →
G3S077	—	0.990	G3S077 →
O35923	—	0.989	O35923 →
P97929	—	0.989	P97929 →
Q3V089	—	0.989	Q3V089 →
D3ZUC6	—	0.989	D3ZUC6 →
Q9BXT5	—	0.988	Q9BXT5 →
O88491	—	0.987	O88491 →
A4IGL8	—	0.987	A4IGL8 →
Q5THK1	—	0.987	Q5THK1 →